Kiniksa Pharmaceuticals
KNSA
176 hedge funds and large institutions have $991M invested in Kiniksa Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 15 closing their positions.
293% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 15
50% more capital invested
Capital invested by funds: $659M → $991M (+$332M)
33% more funds holding
Funds holding: 132 → 176 (+44)
30% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 43
23% more call options, than puts
Call options by funds: $3.13M | Put options by funds: $2.53M
10.05% more ownership
Funds ownership: 87.61% → 97.66% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$80.3M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$20.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.9M |
| 4 |
Goldman Sachs
New York
|
+$12.4M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.46M |
Top Sellers
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$38M |
| 2 |
Morgan Stanley
New York
|
-$23.4M |
| 3 |
BlackRock
New York
|
-$18.9M |
| 4 |
State Street
Boston,
Massachusetts
|
-$17.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.91M |
KNSA Hedge Fund Activity: Q3 2024 in Review
176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2024, worth a combined $991M — up 50% from $659M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new KNSA positions and 15 closed out — a net gain of 44 holders — while 56 added to existing stakes and 43 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $80.3M. The largest seller was HHLR Advisors, cutting an estimated $38M.
- 176 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2024, up from 132 in Q2 2024.
- Funds reported $991M of Kiniksa Pharmaceuticals stock for Q3 2024, up 50% quarter-over-quarter.
- 59 funds opened new Kiniksa Pharmaceuticals positions in Q3 2024 and 15 closed out, a net change of +44 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $80.3M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2024 was HHLR Advisors, an estimated $38M sold.
Based on aggregated 13F filings for Q3 2024.